Administration of Drugs via the CME Medical T34 Syringe Driver Standard Operating Procedure
|
|
- Clifton Norman
- 5 years ago
- Views:
Transcription
1 Administration of Drugs via the CME Medical T34 Syringe Driver Standard Operating Procedure DOCUMENT CONTROL: Version: 3 Ratified by: Quality and Safety Sub Committee Date ratified: 30 May 2017 Name of originator/author: Community Practice Educator Current version reviewed by Pharmacy Team Name of responsible Medicines Management Committee committee/individual: Date issued: 6 December 2017 Review date: May 2020 Target Audience Community Nursing Staff
2 1. Aim 2. Scope This Standard Operating Procedure (SOP) represents current recommended good practice and will ensure the proper action to take regarding the setting up and management of the CME Medical T34 Syringe driver by clinical staff in the Community setting. All registered nurses using the CME T34 Syringe Driver must be personally competent and accountable in the use and operation of the device by attending bespoke training. Evidence of training will be recorded on each staff member s training record. Mandatory annual updates will be provided. 3. Link to overarching policy and/or procedure This SOP is to be used in conjunction with the RDaSH Policy Safe and Secure Handling of Medicines. 4. Procedure 4.1 General Information 4.2 Safety The McKinley T34 Syringe Driver is used across Rotherham Doncaster and South Humber NHS Foundation Trust (RDaSH) in line with the requirements of the National Patient Safety Alert entitled Safer Ambulatory Syringe Drivers (NPSA/2010/RRR019) (2010).. The McKinley T34 is a small battery operated machine, designed to give a continuous subcutaneous infusion in milliliters (ml) per hour over a given period. This method of symptom control, used predominantly in palliative and end of life care provides relief of multiple symptoms e.g. pain, nausea and agitation via a single route. The safe use of the syringe driver requires comprehensive knowledge in order to maintain patient safety. Caution: If a patient is discharged home with a different make of syringe driver, this should be changed to a McKinley T34 device as soon as possible. Lock boxes will fit syringes up to 30ml and should always be used with the CME Medical T34. Lock boxes reduce the risk of accidental or intentional interference with the syringe driver and protect from damage caused by normal daily use or drops within the range of one metre. 4.3 Cleansing, Decontamination and Maintenance All staff must follow standard infection prevention and control precautions including hand hygiene, use of personal protective equipment, decontamination of reusable medical devices, sharps management and Page 2 of 27
3 disposal of healthcare waste. The device must be decontaminated between patients, daily when in use and as and when it becomes dirty or contaminated. Always turn the syringe driver off before cleaning. After patient use decontaminate the unit using lint free cloth such as Tuffi 5. Also clean actuator screw thread and guiding rods to remove debris or other particles. Do not clean the syringe pump with chemicals such as xylene, acetone, or similar solvents. These chemicals can cause damage to components and labels. Do not soak or immerse any part of the syringe driver in any solution. Immersing the pump in liquid will cause damage to components and this will void the guarantee. It is recommended that Tuffi 5 wipes are also used to decontaminate the lock box. All Syringe Drivers will require routine annual maintenance and service as a minimum or when syringe driver warning is indicated on individual syringe drivers. Key Health Solutions will provide maintenance work. Devices due for maintenance can be returned to the designated person for the clinical area, who will then forward the devices onto Key Health Solutions. A declaration of decontamination status for will need completing and attaching to the device prior to sending it for repair or service. 4.4 Storage It is essential that all syringe drivers are accounted for at all times. Hospice Syringe drivers and locked boxes will be stored in a designated place within the hospice. Each syringe driver will have its own case. It will be the responsibility of the nurse who last used the device to clean the syringe driver and lock box adhering to the Standard Infection Prevention and Control Precautions Policy. Community All Community Nursing Teams (Planned and Unplanned) are required to keep an up to date list of the exact location of the Syringe Drivers. (See appendix 1) Syringe Drivers will be stored at the four planned locality bases and a Page 3 of 27
4 designated place for Unplanned. They will be stored in lockable cases and each device will have its own case. It will be the responsibility of the nurse who last used the device to clean the syringe driver and lock box adhering to the Standard Infection Prevention and Control Precautions Policy. The case will be refilled ready for further use and stored in a safe place within the base point. There will be 1 case for each device and these cases will be stored at each base point in the Community. 4.5 Equipment Required Syringe driver McKinley T34 and Lock Box. Ensure within maintenance date. Obtain a new syringe driver if out of date volt alkaline battery Duracell Procell. The average battery life is 3-5 days depending on usage e.g. key presses or backlight use Winged infusion set Saf-T-Intima24Gx0.75 FSP318Yellow Administration set CME McKinley Micro set S (Anti-siphon valve and female luer lock. Length approx. 100cm, priming volume approx. 0.5ml) BD Plastipak luer lock syringe 20ml or 30ml. N.B. luer lock syringes must always be used to ensure secure connection of the infusion set. The pump is calibrated to luer lock and failure to use may result in under or over infusion due to variation in syringe dimensions Combi-stopper to cap the syringe or administration set Transparent adhesive dressing Drugs and diluent prescribed Needle (to draw up drug) Drug additive label Patient s Syringe Driver Prescription and Observation Chart Sharps receptacle Disposable carrying pouch (only if patient is mobile) Instruction procedure manual and equipment, as documented on syringe driver check list Signing in and out sheet completed with the syringe driver serial number date, time, patient name and address (see appendix 2) Page 4 of 27
5 Battery will be removed when device not in use. Syringe driver to be stored in cases provided by Trust. A reciprocal agreement is in place between RDaSH and Doncaster and Bassetlaw Hospital NHS Foundation Trust (DBHFT) for the safe return of syringe drivers to their respective bases. The syringe driver must be returned to base after use. If the patient is admitted to hospital, then it is the responsibility of the nurse who is allocated to the visit to ensure that they retrieve the syringe driver. The responsible nurse will contact the Community Support Manager via using the relevant form. (See appendix 2) An agreement is in place with Doncaster Royal Infirmary (DRI) for devices that turn up with patients that have been admitted to hospital. These devices will be returned to the medical devices unit at DRI. The medical devices unit will then return the device to the Community Support Manager. If devices from DRI are sent home with patients in the community, these will be returned by the Community Support Manager to the medical devices unit at DRI. Admission to the Hospice If a patient is admitted to the hospice with a community syringe driver, the device is swapped to a hospice device within 24 hours and returned to the designated base via the RDASH shuttle. If a patient is discharged from the hospice with a syringe driver, the device should be swapped to a community device within 24 hours and returned to the hospice ASAP. All Hospice device serial numbers are recorded on a database and tracked by the Hospice Ward Clerk. Transferred out of RDaSH The registered nurse must: Record the details and serial number of the syringe driver on the district nurse referral form or on the transfer letter if the patient is discharged to a care home, other hospital or hospice Place a copy of the form in the patient s notes Request that care home, hospital or hospice return the syringe driver to Medical Technical Services Inform Medical Technical Services of the transfer Caution: If a patient is discharged home from a neighbouring hospital (other than Doncaster Royal Infirmary) with a different make of syringe driver, this should be changed over to the McKinley T34 and the other syringe driver returned to the hospital in question as soon as possible. 4.6 Administration Procedure It is good practice for two staff members, one of which must be qualified, to Page 5 of 27
6 undertake the procedure; however, in community settings where there may not be another health professional available, the patient s relative may act as a second signatory to check relevant aspects of the procedure. e.g. Stock levels. See Appendix 3 for indications, advantages and disadvantages of syringe driver 4.7 Involving the patient and family Communication and consultation with the patient and family is essential. Before starting a subcutaneous infusion, the reasons for using this method of administration should be explained to the patient and family. Informed consent for administration should be obtained, in accordance with the Mental Capacity Act 2005 Policy. The discussion is then to be recorded in the nursing care plan. Attention should be paid to both the physical and psychological aspects involved in accepting a new way of receiving medication. Some patients feel that this method of drug delivery is a last resort that their activities will be restricted and that death may be imminent. It is necessary to listen to and answer the patient s questions, acknowledge their concerns and then give explanations and reassurance as appropriate. Community only - The patient and family will be informed that the syringe driver device is on loan to them and must be returned as delivered after use. A signature will be required from the patient or family after discussion. (See appendix 7) The explanation should include the following: The reasons for using a syringe driver How the syringe driver works The siting procedure and site care How the dose of medication can be adjusted to manage symptoms Encouragement to describe symptoms 4.8 Procedure for setting up the syringe driver A registered nurse must calculate the volume of drug that needs to be drawn up from the concentration of the preparation to be used and the prescribed dose. When preparing medicines and disposing of waste materials, the registered nurse must adhere to the following guidance:- Safe and Secure Handling of Medicines Policy SOP for Controlled Drugs Standard Infection Prevention and Control Precautions Policy Sharps Policy Safe Use and Disposal of Sharps and Management of Contamination Injuries Hand Hygiene policy Page 6 of 27
7 NMC Standards of Medicines Management The Medicines Act (1986) Waste Policy A registered nurse must ensure:- The prescription has been completed correctly, perform the calculation and check the medication. Confirm the previous opioid dose, formulation and frequency. Ensure the medication prescribed and the doses are clinically appropriate based on the patient s previous requirements (NPSA, 2008). The diluent will be prescribed on the patient s Syringe Driver Prescription (Syringe Driver prescription chart). For McKinley T34 feature recognition please see appendix 4 Sterile water for injection Advantages Recommended because of its use in reconstituting lyophilized (freeze-dried) Morphine Sulphate More supporting compatibility data Reduces the risk of precipitation with cyclizine lactate Disadvantages Large volumes are hypotonic and can cause infusion site pain Sterile 0.9% Sodium chloride Advantages Recommended with certain drugs e.g. octreotide Less infusion site pain and fewer skin reactions Disadvantages Disadvantages Incompatible with cyclizine Increases likelihood of precipitation when more than one drug is used There is a potential for interaction between drugs in a syringe driver. The compatibility of the drugs and the diluent to be drawn up must be checked prior to mixing. The Palliative Care Formulary (Twycross et al, 2014), The Syringe Driver, Continuous subcutaneous infusions in palliative care (Dickman A and Schneider J, 2011) suggest suitable combinations of drugs. If there are any concerns regarding compatibility: Firstly refer to the compatibility and stability tables for a subcutaneous infusion in a McKinley T34 Syringe pump (appendix 5) Contact the prescriber Page 7 of 27
8 Contact the Specialist Palliative Care Triage or pharmacy If any further concerns out of hours (after doing all of the above) call the on-call Consultant in Palliative Medicine or on-call Pharmacist via DRI switchboard. Ideally syringe driver prescription reviews should take place in working hours only. In Rotherham Doncaster and South Humber NHS Foundation Trust (RDaSH) a combination of no more than 3 dugs should be prescribed on the prescription form or drawn up into a syringe. If more than 3 drugs are required, 2 prescription forms and 2 syringe drivers will be needed. Please seek advice from the Specialist Palliative Care Team. Hospice only 4 drug combinations may be appropriate on an individualised basis only and rationale clearly documented in the medical notes. N.B. Ampules containing a liquid solution may contain an amount in excess of the volume stated on the label. Therefore, measure the volume of liquid as it is drawn up to ensure accuracy of the dose. Select the appropriate syringe size 20ml or 30ml Draw up the prescribed medication Add the diluent up to the required volume Complete the label, including: - Patient name and NHS number - Medicine name and dose - Batch numbers - Diluent used - Route of infusion - Date and time prepared - Initials of the registered nurses preparing the syringe Attach the label to the syringe ensuring that it is flat and not folded. Leave the scale visible so that it can still be read. Skin Site Selection for Subcutaneous Infusions. Where possible involve the patient in the choice of a suitable site. Areas suitable for subcutaneous infusion include those with a good depth of subcutaneous fat, towards the trunk of the body, particularly if the patient s peripheral circulation is compromised Following completion of the procedure document the following in the patient s electronic records -the prescribed medication, dose, dilutant and site of the syringe driver alongside the amount of prescribed medication remaining. (See appendix 2). Note when using Appendix 2:- The CME Medical T34 ambulatory syringe pump is calibrated to operate with BD Plastipak Luer lock syringe brands and sizes. It is programmed to recognise both the brand and the size of syringe being used (commonly 20ml. and 30ml).It will be defaulted using a Prime and Load (Lock on) Programme of a 24 hour delivery system. Page 8 of 27
9 Fill volume Medication and diluents should always be drawn up to the following volumes 20ml syringe draw up to 17ml 30ml syringe draw up to 22ml Acceptable sites Sites to avoid Oedematous areas, including areas affected by lymphedema or ascites. (poor absorption, increased risk of infection) Sites over bony prominences (discomfort and poor absorption) Joints or skin folds (discomfort and movement may displace cannula) Previously irradiated skin (may have poor perfusion - affects drug absorption) Upper abdomen in a patient with an enlarged liver (risk of puncturing the liver capsule) Upper chest wall in a very cachectic patient (risk of pneumothorax) Infected, broken, inflamed or bruised skin Sites of tumour Page 9 of 27
10 Inserting BD Saf-T- Intima Venflon Please note PPE and hand hygiene principles should be adhered to for all procedures. Clean the site with soap and water if the skin is dirty otherwise there is no need to swab the skin Apply the clamp to the line Grasp the pebbled side of the wings of the cannula, pinching the wings firmly together. This locks the needle and prevents it from retracting during insertion Ensure that the needle is point down and bevel uppermost, to guide the cannula through the tissues. This prevents kinking of the cannula. If the needle is not already orientated with the point down open the wings and gently twist the white shield until the needle is correctly positioned Insert the cannula subcutaneously at an angle of less than 45 degrees, lowering the initial angle of the cannula to a level more parallel to the skin (caution on the chest wall) and advance to the hilt of the cannula Open the wings (pebbled side down) flat against the skin Apply transparent adhesive dressing over the insertion site and the cannula wings Apply firm finger- tip pressure over the wings of the cannula (avoiding the centre where the needle retracts) simultaneously grasp the pebbled end of the coloured/white cylinder shield and pull in a straight continuous motion until the needle has fully with drawn into the cylinder and pops off Gently remove cylinder from the cannula port, if it has not released spontaneously, exposing the adapter with the rubber bung Place the needle shield in the sharps bin Change the site every 7 days or as necessary depending on the condition of the skin N.B. Te Saf-T-Intima cannot be primed when using the McKinley T34. When setting up the syringe driver the primed extension line is connected directly to the un-primed Saf-T-Intima The registered nurse must prepare the syringe and confirm the patient s identity as on prescription Check the battery life by pressing the INFO Key twice *** Prepare syringe and contents and cap the syringe. Press STOP Press and hold INFO key to deactivate keypad lock If the infusion complete alarm has activated, press YES to confirm end of infusion Switch syringe driver OFF Clamp Saf-T-Intima Raise the barrel clamp arm Remove old syringe Page 10 of 27
11 Follow instructions on page 18 Power on and pre-loading When Start infusion? screen displays, connect the infusion line to the syringe, release the clamp on the Saf-t- Intima and press YES *** For community use the battery will need changing when the device registers at 40% battery life left. Bolus dose of medication If the patient has uncontrolled symptoms prior to setting up the McKinley T34, it may be necessary to give a PRN dose of medication. A separate Saf-T- Intima 24Gx0.75 FSP318 Yellow should be inserted for the purpose of giving PRN doses. A Swan Lock needle free device should be attached to the Saf-T- Intima port. Temporary interruption to the infusion - Hospice This is not normal practice in a community setting and should only be used in exceptional circumstances e.g. showering or bathing. N.B. Topping the infusion will delay the end time of the infusion Stopping the Infusion Press STOP unlock the keypad and turn the syringe driver OFF. Clamp the Saf-T- Intima Disconnect the syringe driver. DO NOT REMOVE THE SYRINGE FROM THE PUMP Cap the Saf-T-Intima and infusion line to minimize cross infection. Record time and reason why infusion stopped on Syringe Driver Observation Chart Resuming the Infusion Check that the prescription, syringe label and patient details are correct Reconnect the line to the syringe on the pump maintaining asepsis Press and hold ON button The screen will request confirmation of size and brand of syringe Press YES to confirm The screen will display Press YES to Resume NO for New Syringe Press YES to resume The screen will display remaining volume/ duration/ rate of infusion Ensure information is correct as prescribed Press YES to confirm Unclamp Saf-T-Intima Screen will display Start Infusion? Press YES to start infusion Press and hold INFO key to lock the keypad Replace the Lock Box Page 11 of 27
12 Record on the Syringe Driver Observation chart the time the infusion was recommenced N.B. If NO for New Syringe is pressed the remaining infusion will be reset to deliver over the next 24hrs at a different rate, and the infusion will be incorrect. If NO for New Syringe has been pressed in error. Discard the remainder of the syringe contents, prepare, and set up a new syringe. In a community setting the following procedure should not be applicable as staff will check the battery status before commencing each 24 hour regime. Changing the battery during an infusion When near the end of the battery alert sounds, it indicates that the battery should be changed within the next half hour Press STOP and apply clamp to Saf-T-Intima Insert new battery Restart the syringe driver Reconfirm syringe size and brand Press YES to resume Reconfirm volume and duration and rate of infusion Press YES to recommence the infusion Lock the keypad Following completion of the procedure all patient records will be updated and signed by the registered nurse. (For paper documentation see appendix 2). Records will also include those accessed on System One. What to do if there is an occlusion in the extension line Check that the Saf-t-Intima is not clamped Check the extension line and Saf-t-Intima for any kinking straighten if kinked Check the syringe, extension line and Saf-t-Intima for any signs of crystallization of the solution. If crystallization detected prepare and fit new syringe, extension line and change Saf-t-Intima site If no physical reason for the occlusion is detected resite the Saf-t- Intima If occlusion is still present change the site, extension line and syringe N.B. During an occlusion the pump s Post Occlusion Reduction System will reverse the operation of the motor and drive the actuator backwards, otherwise the pressure build up could cause a surge of fluid into the patient on release of the occlusion. When the pump is resumed/restarted following the backward movement of the actuator, time will be added to the time remaining to protect the original calculated rate. Page 12 of 27
13 Procedure for releasing a trapped foreign object from the actuator (See appendix 6) WARNING: IF A FOREIGN OBJECT IS TRAPPED IN FRONT OF OR BEHIND THE ACTUATOR DURING PRE-LOADING (AUTOMATIC ACTUATOR MOVEMENT) OR WHEN MANUALLY ADJUSTING THE ACTUATOR, THE USER SHOULD: Ignore screen prompts as the prompt that may display will be in relation to alarm activation and NOT the trapped object Turn the syringe driver OFF Raise the barrel clamp arm and turn it to the left or right to keep it in the raised position Turn the syringe driver ON Turn and lower the barrel clamp arm Use the FF key (or BACK key) to move the actuator in order to release the object 4.9 Incident Reporting Systems are in place within Rotherham Doncaster and South Humber NHS Foundation Trust to report and manage incidents, near misses and serious untoward incidents involving syringe pumps. Staff should be familiar with the reporting process and the Incident Reporting Policy. Acknowledgements McKinley T34 Ambulatory Syringe Pump Operations Manual (2011) Illustrations courtesy of CME McKinley Medical CME McKinley UK Ltd Kincraig Business Park, Kincraig Road, Blackpool, FY2 0PJ Tel: Links to Associated Documents Aseptic technique and Aseptic Non Touch Technique Policy Lifecycle of Clinical & Corporate Records Policy Medical Devices Policy The Medicines Act (1986) Mental Capacity Act 2005 Policy Incident Reporting Policy Policy for Consent to Examination and Treatment. SOP for Controlled Drugs Standard Infection Prevention and Control Precautions Policy Sharps Policy Safe Use and Disposal of Sharps and Management of Contamination Injuries Page 13 of 27
14 Hand Hygiene Policy NMC Standards of Medicines Management Waste Policy 6. References and Literature review British Medical Association and the Royal Pharmacological Society of Great Britain. (2013) British National Formulary No 64 London. BMA and RPSGB. Dickman A and Schneider J (2011) The Syringe Driver. Continuous subcutaneous infusions in palliative care 3rd edition, Oxford University Press, Oxford Perdue, C. (2004) The syringe driver an aid to delivering symptom control. Nursing Times, 100, 13. pp Medicines Act HMSO: London Mental Capacity Act (2005) DOH: London Mitten, T. (2001) Subcutaneous drug infusions: a review of problems and solutions. International Journal of Palliative Nursing, 7,2. pp National Patient Safety Agency (2008) Reducing dosing errors with Opioid Medicines Rapid Response Report 05 National Patient Safety Agency (2010) Safer ambulatory syringe drivers Rapid Response Report 019 NMC (2008) The Code: Standards of conduct, performance and ethics for nurses and midwives, Nursing and Midwifery council, London NMC (2008) Standards for medicines management, Nursing and Midwifery Council, London Twycross, R, Howard,P and Wilcock A (2014) (eds) Palliative Care Formulary 5th edition, Nottingham, palliativedrugs.com Ltd. Wilson J. (2001) Infection Control in Clinical Practice. Bailliere Tindall. London pp Appendices Appendix 1 Appendix 2 Appendix 3 Syringe Driver base information Subcutaneous syringe driver instruction and observation chart for McKinley T34 and continuation sheet Indications, Advantages and Disadvantages for use of Syringe Driver Page 14 of 27
15 Appendix 4 Appendix 5 Appendix 6 Appendix 7 McKinley T34 Feature Recognition McKinley Syringe pump compatibility tables Procedure for releasing a trapped object from the actuator Form for the patient regarding loan of syringe driver Page 15 of 27
16 SYRINGE DRIVE BASE INFORMATION Appendix 1 SYRINGE DRIVER IDENTIFICATION CODE CLUSTER AREA IN USE/NOT IN USE nb. IF IN USE PLEASE REFER TO THE RECORD SHEET STAFF SIGNATURE Page 16 of 27
17 DAILY SET UP MONITORING PROGRESS Appendix 2 SUBCUTANEOUS SYRINGE DRIVER INSTRUCTION AND OBSERVATION CHART FOR MCKINLEY T34 PRESCRIPTION DETAILS [for completion by the prescriber] a separate form must be completed for each syringe driver DRUG DOSE DILUENT PHARMACY a ALLERGY STATUS Date 1. Please circle Route SC 2. Duration 3. of flow 4. Please circle 12 hours 24 hours Water for injection or Normal Saline The patient will be reviewed by the attending clinician at each attendance and, where there has been a change of circumstances, will refer to the prescriber for any necessary treatment changes or need for review. If, as the prescriber, you wish to review the patient on a particular date, please stipulate below - Review date:.. Prescriber name: Signature: Practice:.. ADMINISTRATION & OBSERVATION DETAILS [for completion by administering clinician] WARD OR BASEPOINT The patient will be reviewed by the attending clinician at each attendance and, where there has been a change of circumstances, will refer to the prescriber for any necessary treatment changes or need for review. ADMINISTRATION 1 Day and Date OBSERVATIONS 2 Time Start time of infusion: Site appearance 6 : Syringe size used 17ml infusion in 20ml syringe Syringe/line contents clear 3 - OK to continue? 20ml or 30ml 22ml infusion in 30ml syringe Infusion rate setting as at set up? [Y/N] Syringe Driver serial No.: Battery Status [%]: Infusion time remaining [HH:MM] Infusion rate [ml/hr]: Volume still to be infused (vtbi) [ml] Site used 5 : Site Appearance 6 : Is the VTBI correct for time remaining [Y/N] Drawn up by: Checked by: Volume infused [ml] Details of any problems & actions taken: Battery status [%] 4 Is the key pad locked? [Y/N] Observer s initials If syringe contents discarded: Volume discarded: Date & time: Discharged by: Checked: 1. To be completed each time syringe driver is loaded 4. Change battery when less than 10% (ward ) or 40% (community) 2. WARD - Completed 30 minutes after loading and then every 4 hours 5. Document insertion site of winged infusion COMMUNITY Complete at set up, at each subsequent visit and at syringe change 6. Appearance: Use code below 3. If contents of syringe look cloudy, precipitation has occurred. STOP infusing and contact NP (no problem) P (pain) I (inflammation) prescriber. Refer to policy for guidance on checking compatibility SW (swelling) B (bleeding) H (hardening) PATIENT DETAILS [Affix label if available] NHS Number:.. Surname: Forename(s): Address:... DOB:.. a. Pharmacy: Only complete if this form is used on a ward. NOT required for community use. Page 1 Page 17 of 27
18 DAILY SET UP MONITORING PROGRESS DAILY SET UP MONITORING PROGRESS SUBCUTANEOUS SYRINGE DRIVER CONTINUATION SHEET ADMINISTRATION & OBSERVATION DETAILS WARD OR BASEPOINT NAME The patient will be reviewed by the attending clinician at each attendance and, where there has been a change of circumstances, will refer to the prescriber for any necessary treatment changes or need for review. ADMINISTRATION 1 Day and Date OBSERVATIONS 2 Time [HH:MM] Start time of infusion: Site appearance 6 : Syringe size used 17ml infusion in 20ml syringe Syringe/line contents clear 3 - OK to continue? [Y/N] 20ml or 30ml 22ml infusion in 30ml syringe Infusion rate setting as at set up? [Y/N] Syringe Driver serial No.: Battery Status [%]: Infusion time remaining [HH:MM] Infusion rate [ml/hr]: Volume still to be infused (vtbi) [ml] Site used 5 : Site Appearance 6 : Is the VTBI correct for time remaining [Y/N] Drawn up by: Checked by: Volume infused [ml] Details of any problems & actions taken: Battery status [%] 4 Is the key pad locked? [Y/N] If syringe contents discarded: Volume discarded: Observer s initials Date & time: Discharged by: Checked: ADMINISTRATION & OBSERVATION DETAILS WARD OR BASEPOINT NAME The patient will be reviewed by the attending clinician at each attendance and, where there has been a change of circumstances, will refer to the prescriber for any necessary treatment changes or need for review. ADMINISTRATION 1 Day and Date OBSERVATIONS 2 Time [HH:MM] Start time of infusion: Site appearance 6 : Syringe size used 17ml infusion in 20ml syringe Syringe/line contents clear 3 - OK to continue? [Y/N] 20ml or 30ml 22ml infusion in 30ml syringe Infusion rate setting as at set up? [Y/N] Syringe Driver serial No.: Battery Status [%]: Infusion time remaining [HH:MM] Infusion rate [ml/hr]: Volume still to be infused (vtbi) [ml] Site used 5 : Site Appearance 6 : Is the VTBI correct for time remaining [Y/N] Drawn up by: Checked by: Volume infused [ml] Details of any problems & actions taken: Battery status [%] 5 Is the key pad locked? [Y/N] If syringe contents discarded: Volume discarded: Observer s initials Date & time: Discharged by: Checked: 1. To be completed each time syringe driver is loaded 2. WARD - Completed 30 minutes after loading and then every 4 hours COMMUNITY Complete at set up, at each subsequent visit and at syringe change 3. If contents of syringe look cloudy, precipitation has occurred. STOP infusing and contact prescriber. Refer to policy for guidance on checking compatibility 4. Change batter when less than 10% (ward ) or 40% (community) 5. Document insertion site of winged infusion 6. Appearance: use code below NP (no problem) P (pain) I (inflammation) SW (swelling) B (bleeding) H (hardening) Page 18 of 27 Page
19 DAILY SET UP MONITORING PROGRESS DAILY SET UP MONITORING PROGRESS SUBCUTANEOUS SYRINGE DRIVER CONTINUATION SHEET ADMINISTRATION & OBSERVATION DETAILS WARD OR BASEPOINT NAME The patient will be reviewed by the attending clinician at each attendance and, where there has been a change of circumstances, will refer to the prescriber for any necessary treatment changes or need for review. ADMINISTRATION 1 Day and Date OBSERVATIONS 2 Time [HH:MM] Start time of infusion: Site appearance 6 : Syringe size used 17ml infusion in 20ml syringe Syringe/line contents clear 3 - OK to continue? 20ml or 30ml 22ml infusion in 30ml syringe [Y/N] Infusion rate setting as at set up? [Y/N] Syringe Driver serial No.: Battery Status [%]: Infusion time remaining [HH:MM] Infusion rate [ml/hr]: Volume still to be infused (vtbi) [ml] Site used 5 : Site Appearance 6 : Is the VTBI correct for time remaining [Y/N] Drawn up by: Checked by: Volume infused [ml] Details of any problems & actions taken: If syringe contents discarded: Volume discarded: Date & time: Discharged by: Checked: Battery status [%] 4 Is the key pad locked? [Y/N] Observer s initials ADMINISTRATION & OBSERVATION DETAILS WARD OR BASEPOINT NAME The patient will be reviewed by the attending clinician at each attendance and, where there has been a change of circumstances, will refer to the prescriber for any necessary treatment changes or need for review. ADMINISTRATION 1 Day and Date OBSERVATIONS 2 Time [HH:MM] Start time of infusion: Site appearance 6 : Syringe size used 17ml infusion in 20ml syringe Syringe/line contents clear 3 - OK to continue? [Y/N] 20ml or 30ml 22ml infusion in 30ml syringe Infusion rate setting as at set up? [Y/N] Syringe Driver serial No.: Battery Status [%]: Infusion time remaining [HH:MM] Infusion rate [ml/hr]: Volume still to be infused (vtbi) [ml] Site used 5 : Site Appearance 6 : Is the VTBI correct for time remaining [Y/N] Drawn up by: Checked by: Volume infused [ml] Details of any problems & actions taken: Battery status [%] 5 Is the key pad locked? [Y/N] If syringe contents discarded: Volume discarded: Observer s initials Date & time: Discharged by: Checked: 4. Change batter when less than 10% (ward ) or 40% (community) 5. Document insertion site of winged infusion 6. Appearance: use code below NP (no problem) P (pain) I (inflammation) SW (swelling) B (bleeding) H (hardening)= Page.. 4. To be completed each time syringe driver is loaded 5. WARD - Completed 30 minutes after loading and then every 4 hours COMMUNITY Complete at set up, at each subsequent visit and at syringe change 6. If contents of syringe look cloudy, precipitation has occurred. STOP infusing and contact prescriber. Refer to policy for guidance on checking compatibility Page 19 of 27
20 Appendix 3 Indications for the use of a syringe driver The inability of the patient to swallow or absorb oral drugs because of: Intestinal Obstruction Persistent Vomiting Dysphagia Mouth Throat or Oesophageal Tumour Altered Level of Consciousness Malabsorption Profound Weakness Advantages Plasma drug levels are maintained preventing peaks and troughs Effective symptom control without repeated injections Control of multiple symptoms with a combination of drugs Mobility and independence maintained for some patients Disadvantages/Risks Medication errors relating to drug or dose Inflammation or infection may occur at skin site Drug/patient and drug/diluent incompatibility Page 20 of 27
21 McKinley T34 Feature Recognition Appendix 4 Barrel clamp arm.secures syringe and detects brand and size Collar sensor detects correct loading of syringe collar Plunger sensor detects correct loading of the syringe plunger Actuator Info key (c) key Key Yes/Start No/Stop FF (Forward) Back (Reverse) On/Off key drives the syringe plunger to deliver the syringe contents (a) shows infusion summary, protocol parameters, battery level (b) when pump is paused, access the main menu activates/deactivates keypad lock UP arrow (a) scrolls between options (b) increases infusion parameters Down arrow (a) scrolls between options (b) decreases infusion parameters during programming/ titration Confirms selection and starts infusion (a) stops infusion (b) takes the user back a step during programming (a) moves actuator forward when no syringe in place and barrel clamp arm is down (b) accesses purge function (if enabled) moves actuator backward when no syringe is in place and barrel clamp arm is down Switches the pump on and off Infusion LED light. A green indicator lights: (a) during system self-test (b) intermittently to indicate infusion delivery A red indicator light: (a) continuously to indicate an alarm state (b) when pump paused/on stand-by mode Page 21 of 27
22 Appendix 5 Compatibility and stability tables for a subcutaneous infusion in a McKinley T34 Syringe Pump Table 1: Subcutaneous Morphine Infusion Diluent: Water for injections The figures in these tables are not clinical doses to prescribe. Most patients do not need such large amounts of medication. Refer to the relevant guidelines to obtain the usual dose range for each of the medications. Use the minimum effective dose and titrate according to response. Use the table to check for concentrations that are stable for 24 hours; their use is unlicensed. Drug Combination Concentrations of two drug combinations that are physically stable for 24 hours 17ml in 20ml syringe 22ml in 30ml syringe Morphine Sulphate Cyclizine 300mg 150mg 380mg 150mg Morphine Sulphate Glycopyrronium bromide 300mg 380mg Morphine Sulphate Haloperidol 400mg 500mg Morphine Sulphate Hyoscine butylbromide 300mg 120mg 380mg 120mg Morphine Sulphate Hyoscine hydrobromide 450mg 580mg Morphine Sulphate Levomepromazine 300mg 380mg Morphine Sulphate Metoclopramide 120mg 60mg 150mg 70mg Morphine Sulphate Midazolam 300mg 30mg 380mg 3 Morphine Sulphate Octreotide 400mg 400 micrograms 500mg 500 micrograms Drug Combination Concentrations of three drug combinations that are physically stable for 24 hours 17ml in 20ml syringe 22ml in 30ml syringe Morphine Sulphate Cyclizine Haloperidol 40mg 50mg Morphine Sulphate Haloperidol Midazolam Morphine Sulphate Hyoscine butylbromide Midazolam Morphine Sulphate Metoclopramide Midazolam Morphine Sulphate Midazolam Levomepromazine 2mg 20mg 50mg 40mg 60mg 50mg 30mg 7mg 180mg 3mg 130mg 6mg 2 60mg 50mg 7 60mg 40mg 230mg 12mg Page 22 of 27
23 Table 2: Subcutaneous Diamorphine infusion in a McKinley T34 Syringe Pump Diluent: Water for injections The figures in these tables are not clinical doses to prescribe. Most patients do not need such large amounts of medication. Refer to the relevant guidelines to obtain the usual dose range for each of the medications. Use the minimum effective dose and titrate according to response. Use the table to check for concentrations that are stable for 24 hours; their use is unlicensed. Drug Combination Diamorphine Cyclizine Diamorphine Glycopyrronium bromide Diamorphine Haloperidol Diamorphine Hyoscine butylbromide Diamorphine Hyoscine hydrobromide Diamorphine Levomepromazine Diamorphine Metoclopramide Diamorphine Midazolam Diamorphine Octreotide Drug Combination Diamorphine Cyclizine Haloperidol Diamorphine Haloperidol Midazolam Diamorphine Hyoscine butylbromide Midazolam Diamorphine Levomepromazine Metoclopramide Diamorphine Levomepromazine Midazolam Concentrations of two drug combinations that are physically stable for 24 hours 17ml in 20ml syringe 22ml in 30ml syringe 340mg 150mg mg 1000mg 120mg 1000mg 850mg 1000mg 8 560mg 80mg micrograms 440mg 150mg 550mg 1000mg 1000mg 120mg 1000mg 1000mg 1000mg 1 720mg 80mg 550mg 900 micrograms Concentrations of three drug combinations that are physically stable for 24 hours 17ml in 20ml syringe 340mg 150mg 800mg 7mg 6 120mg 80mg 20mg 850mg 50mg 850mg 50mg 30mg 22ml in 30ml syringe 440mg 150mg 1000mg 80mg 150mg mg 60mg 1000mg 60mg 40mg Page 23 of 27
24 Table 3: Subcutaneous Oxycodone infusion in a McKinley T34 Syringe Pump Diluent: Water for injections The figures in these tables are not clinical doses to prescribe. Most patients do not need such large amounts of medication. Refer to the relevant guidelines to obtain the usual dose range for each of the medications. Use the minimum effective dose and titrate according to response. Use the table to check for concentrations that are stable for 24 hours; their use is unlicensed. If the /ml preparation of oxycodone injection is used, and the 24 hour dose of oxycodone exceeds 60mg, an alternative opioid may be needed for breakthough pain. Drug Combination Oxycodone Cyclizine Concentrations of two drug combinations that are physically stable for 24 hours 17ml in 20ml syringe Do not mix - Incompatible 22ml in 30ml syringe Do not mix - Incompatible Oxycodone Haloperidol Oxycodone Hyoscine butylbromide Oxycodone Hyoscine hydrobromide Oxycodone Levomepromazine Oxycodone Metoclopramide Oxycodone Midazolam Oxycodone Octreotide 140mg 140mg 40mg 130mg 120mg 80mg 40mg 80mg 40mg 80mg 400 micrograms 180mg 180mg 50mg 160mg 150mg 50mg 50mg 500 micrograms Drug Combination Oxycodone Haloperidol Hyoscine butylbromide Concentrations of three drug combinations that are physically stable for 24 hours 17ml in 20ml syringe 80mg 2mg 22ml in 30ml syringe 120mg Oxycodone Haloperidol Hyoscine hydrobromide Oxycodone Haloperidol Midazolam Oxycodone Levomepromazine Hyoscine butylbromide 80mg 2mg 1000 micrograms 80mg 2mg 1 80mg 20mg 20mg 2 120mg Page 24 of 27
25 Table 4: Subcutaneous Alfentanil infusion in a McKinley T34 Syringe Pump Diluent: Water for injections The figures in these tables are not clinical doses to prescribe. Most patients do not need such large amounts of medication. Refer to the relevant guidelines to obtain the usual dose range for each of the medications. Use the minimum effective dose and titrate according to response. Use the table to check for concentrations that are stable for 24 hours; their use is unlicensed. Drug Combination Alfentanil Cyclizine Alfentanil Glycopyrronium bromide Alfentanil Haloperidol Alfentanil Hyoscine butylbromide Alfentanil Hyoscine hydrobromide Alfentanil Levomepromazine Alfentanil Metoclopramide Alfentanil Midazolam Alfentanil Octreotide Drug Combination Concentrations of two drug combinations that are physically stable for 24 hours 17ml in 20ml syringe 4mg 150mg 7mg 120mg 7mg 7mg 40mg 2mg 60mg 3mg 50mg 6mg 800 micrograms 22ml in 30ml syringe 150mg 8mg 8mg 120mg 50mg 3mg 80mg 60mg 8mg 900 micrograms Concentrations of three drug combinations that are physically stable for 24 hours Alfentanil Haloperidol Midazolam Alfentanil Hyoscine butylbromide Levomepromazine Alfentanil Metoclopramide Midazolam Alfentanil Levomepromazine Midazolam 17ml in 20ml syringe 4mg 3 120mg 2 3mg 3 20mg 3mg 80mg 30mg 22ml in 30ml syringe 6mg 4 7mg 120mg 2 3mg 4 30mg 40mg 1. Dickman A: The syringe driver: continuous subcutaneous infusions in palliative care. 2nd Edition, OUP. 2. Palliative care drug information online Page 25 of 27
26 Page 26 of 27 Appendix 6
27 Appendix 7 You have been loaned a syringe driver by Rotherham Doncaster and South Humber NHS Foundation Trust. Make and Model... Serial Number... This syringe driver will be cleaned, maintained and tested to ensure it is, and remains fit for purpose by the Nursing team. We have included an instruction manual for the unit that you have been given. Please ensure that; The driver is kept dry It is handled with care Delivered by (Print name)...rdash Employee Instruction given - Date...Signature... Syringe driver accepted by (print name)...patient/carer Date accepted... By accepting this machine I agree to the above. Signature......Patient/carer Advice available from... Please contact... for any issues or to return the unit. The equipment specified remains the property of Rotherham Doncaster and South Humber NHS Foundation Trust and must be returned to the contact above in the condition it was received in when no longer required. Page 27 of 27
Syringe Drivers. Back to top
Page 1 of 8 Syringe Drivers Introduction Indications for use Advantages Method Siting syringe driver Boost facility Transfer to hospital/hospice syringe driver drugs Drug compatibility P.r.n medication
More informationSyringe driver in Palliative Care
Syringe driver in Palliative Care Introduction: Syringe drivers are portable, battery operated devices widely used in palliative care to deliver medication as a continuous subcutaneous infusion over 24
More informationPHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS
PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS The benefits of prefilled syringes for palliative care from the hospital pharmacy service In
More informationSyringe Pumps: Guidance for the use with babies, children and young people in the community setting within Worcestershire
Syringe Pumps: Guidance for the use with babies, children and young people in the community setting within Worcestershire Syringe Pumps: Guidance for the use with babies, children and young people in the
More informationADULT SYRINGE DRIVER PROTOCOL (T34)
ADULT SYRINGE DRIVER PROTOCOL (T34) Version Date Purpose of Issue/Description of Change Review Date 3 May 2016 Guidelines for T34 syringe driver May 2018 Status Publication Scheme FOI Classification Function/Activity
More information[Type text] Anticipatory Medication STAT dose and Syringe Driver Guidance [Type text]
[Type text] Anticipatory Medication STAT dose and Syringe Driver Guidance [Type text] Patients with egfr greater than 30mL/min Patients with egfr less than 30mL/min Symptom Drug Dose Symptom Drug Dose
More informationEssential Syringe Driver Training for T 34. Elaine Bird St Luke s Hospice
Essential Syringe Driver Training for T 34 Elaine Bird St Luke s Hospice Aim For all practitioners to be accountable for their individual competence and capability when caring for a resident with a T34
More informationEducation for self administration of intravenous therapy HOME IV THERAPY. 30 minute - Baxter Pump Tobramycin
HOME IV THERAPY Tobramycin Tobramycin Check the order on the drug chart This can change when the results from your blood test come through. Your doctor will change the order, if required. A copy of the
More informationPAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE
PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE Reference: DCM029 Version: 1.1 This version issued: 07/06/18 Result of last review: Minor changes Date approved by owner (if applicable): N/A
More informationUSE OF MCKINLEY T34 SYRINGE DRIVER
USE OF MCKINLEY T34 SYRINGE DRIVER Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review date (when this version goes out
More informationClatterbridge Centre for Oncology
Clatterbridge Centre for Oncology CONTENTS 1. Why and when to use a syringe driver 2. Siting the syringe driver 3. Mixing and measuring 4. Setting up the syringe driver 5. Drug information 6. Common problems
More informationALLERGIES/ SENSITIVITIES This section must be completed before prescribing/administering any drug
COMMUNITY PRESCRIPTION CHART All entries should be in CAPITAL letters and in indelible black ink. If medications/ doses are stopped, cross through the relevant line clearly to avoid error. GP: PRESCRIBER
More informationCONTROLLED DOCUMENT. Guidelines for the use of subcutaneous hydration in palliative care (hypodermoclysis) Controlled Document Number: CG259
Guidelines for the use of subcutaneous hydration in palliative care (hypodermoclysis) CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: Controlled Document Number: Version Number: 1 Controlled Document Sponsor:
More informationMcKinley T34 Syringe Pump Resource Pack
McKinley T34 Syringe Pump Resource Pack ADULTS 2019 Reviewed February 2019 Datix Ref: 1689-50603 Page 1 Contents Page Accountability and Responsibility. 3 Aims and Objectives. 3 Indications for use 4 Infusion
More informationPatient Information Publications Warren Grant Magnuson Clinical Center National Institutes of Health
Warren Grant Magnuson Clinical Center National Institutes of Health What is a subcutaneous injection? A subcutaneous injection is given in the fatty layer of tissue just under the skin. A subcutaneous
More informationRenal Prescribing at End of Life Guidance for Anticipatory prescribing for patients in renal failure (egfr<30) at the end of life
Guidance for Anticipatory prescribing for patients in renal failure (egfr
More informationUse of the Graseby MS26 Syringe Driver For Palliative Care Within West Lothian
West Lothian Healthcare NHS Trust Use of the Graseby MS26 Syringe Driver For Palliative Care Within West Lothian Training Pack Welcome to the West Lothian Healthcare NHS Trust Syringe Driver training pack.
More informationAdult Palliative and Supportive Care: Ambulatory Syringe Pump Policy including Symptom Management Guidelines
The States of Jersey Department for H ealth & Social Services Adult Palliative and Supportive Care: Ambulatory Syringe Pump Policy including Symptom Management Guidelines [CME McKinley T34 (ml/hour)] March
More informationMcKinley T34 Syringe Pump Policy and Procedure
McKinley T34 Syringe Pump Policy and Procedure Author(s) & Designation Lead Clinician if appropriate In consultation with Practice Education Facilitator, Syringe Driver Training Lead Pharmacist Community
More informationPAIN MANAGEMENT Person established taking oral morphine or opioid naive.
PAIN MANAGEMENT Person established taking oral morphine or opioid naive. Important; it is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
More informationSYRINGE DRIVER MEDICATIONS
SYRINGE DRIVER MEDICATIONS Christine Hull & Anita Webb Staff Nurses, Hospice in the Home 2015 Analgesics:- Groups of Medication used in Syringe Drivers Morphine sulphate Diamorphine Oxycodone Alfentanil
More informationCare of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.
Care of the Dying Early diagnosis of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance covers the prescribing and management of patients
More informationRenal Palliative Care Last Days of Life
Renal Palliative Care Last Days of Life Introduction This guideline is an aid to clinical decision-making and good practice for patients with stage 4-5 chronic kidney disease (egfr
More informationAlgorithms for Symptom Management. In End of Life Care
Algorithms for Symptom Management In End of Life Care The Use of Drugs Beyond Licence (off label) -The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK regulates the activity of the
More informationIMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION ALPROLIX [pronounced all prō liks] Coagulation Factor IX (Recombinant), Fc Fusion Protein This leaflet is part III of a three-part "Product Monograph" published when ALPROLIX
More informationStandard operating procedures for preparation and administration of intramuscular injections. No Action Rationale
Standard operating procedures for preparation and administration of intramuscular injections Preparation Overview No Action Rationale 1 Collect and check all equipment 2 Check that the packaging of all
More informationIMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION ALPROLIX [pronounced all prō liks] Coagulation Factor IX (Recombinant), Fc Fusion Protein This leaflet is part III of a three-part "Product Monograph" published when ALPROLIX
More informationA step-by-step preparation guide
A step-by-step preparation guide For needle and needle-free systems This guide provides detailed instructions on the reconstitution, dilution, and storage of VELETRI. It is intended to be used after your
More informationAdult Palliative and Supportive Care: Ambulatory Syringe Driver Policy (including Symptom Management Guidelines)
Adult Palliative and Supportive Care: Ambulatory Syringe Driver Policy (including Symptom Management Guidelines) (CME McKinley T34 (ml/hour)) 2012 Page 1 of 52 FAMILY NURSING & HOME CARE RATIFICATION FORM
More informationEVOGAM. Information for patients Evogam NZ Patient Brochure Update FA3
EVOGAM Information for patients 11179 Evogam NZ Patient Brochure Update FA3 Information for patients and caregivers about EVOGAM This booklet is designed to help you follow the training you will have been
More informationATI Skills Modules Checklist for Central Venous Access Devices
For faculty use only Educator s name Score Date ATI Skills Modules Checklist for Central Venous Access Devices Student s name Date Verify order Patient record Assess for procedure need Identify, gather,
More informationIsle of Wight Syringe Driver Compatibility Guidelines
Isle of Wight Syringe Driver Compatibility Guidelines Produced by The Earl Mountbatten Hospice, Isle of Wight Written January 2015, revision due January 2018 This guideline is available as a paper pocketbook
More informationPolicy and Procedure for the use of the CME MEDICAL McKinley T34 Syringe Driver for Adults in Palliative Care
Lincolnshire Community Health Services NHS Trust United Lincolnshire Hospitals NHS Trust St Barnabas Lincolnshire Hospice Working in partnership Policy and Procedure for the use of the CME MEDICAL McKinley
More informationEVOGAM. Information for patients Evogam 2014 NZ Patient Brochure Update v11
EVOGAM Information for patients 11881 Evogam 2014 NZ Patient Brochure Update v11 Information for patients and caregivers about EVOGAM This booklet is designed to help you follow the training you will have
More informationInstructions for Use HEMLIBRA (hem-lee-bruh) (emicizumab-kxwh) injection, for subcutaneous use
Instructions for Use HEMLIBRA (hem-lee-bruh) (emicizumab-kxwh) injection, for subcutaneous use Be sure that you read, understand, and follow the Instructions for Use before injecting HEMLIBRA. Your healthcare
More informationSupportive Care. End of Life Phase
Supportive Care End of Life Phase Guidelines for Health Care Professionals In the care of patients with established renal failure who are in the last days of life References: Chambers E J (2004) End of
More informationPAIN MANAGEMENT Patient established on oral morphine or opioid naive.
PAIN MANAGEMENT Patient established on oral morphine or opioid naive. Important; It is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
More informationA step-by-step preparation guide
A step-by-step preparation guide This guide provides detailed instruction on the reconstitution, dilution, and storage of Veletri (epoprostenol) for Injection. It is intended to be used after your healthcare
More informationCare of the Dying Management in Severe Renal Failure
Care of the Dying Management in Severe Renal Failure Clinical Guideline Early recognition of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance
More informationEnd of life prescribing guidance
End of life prescribing guidance Introduction This guidance has been prepared to ASSIST IN DECISION MAKING for the prescribing and monitoring of medicines useful in the management of symptoms commonly
More informationEAST LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE
EAST LANCASHIRE SPECIALIST PALLIATIVE CARE TEAM EAST LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE Reviewed and updated August 2009 Next review date August 2011 Approved
More informationPatient/Carer instructions for the administration of Subcutaneous Cytarabine
Patient/Carer instructions for the administration of Subcutaneous Cytarabine This document covers the following information: What cytarabine is What subcutaneous means What happens if you decide to inject
More informationCentral venous access devices for children with lysosomal storage disorders
Great Ormond Street Hospital for Children NHS Foundation Trust: Information for Families Central venous access devices for children with lysosomal storage disorders This information explains about central
More informationPolicy and Protocol for the use of the CME McKinley T34 Syringe Driver for Adults in Palliative Care
Policy and Protocol for the use of the CME McKinley T34 Syringe Driver for Adults in Palliative Care Version: 1.6 New or Replacement: Policy number: Approved by: Date approved: Name of authors: Name of
More informationPRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT
PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT A collaboration between: St. Rocco s Hospice, Bridgewater Community Healthcare NHS Trust, NHS Warrington Clinical Commissioning Group,
More informationPOLICY / PROCEDURE FOR THE USE OF THE McKinley T34 SYRINGE DRIVER
POLICY / PROCEDURE FOR THE USE OF THE McKinley T34 SYRINGE DRIVER This is a working document and any changes that become necessary to this policy must be notified in writing to the Macmillan Pharmacist
More informationALPROLIX Coagulation Factor IX (Recombinant), Fc Fusion Protein INSTRUCTIONS FOR USE Do not Do not YOUR KIT CONTAINS:
ALPROLIX Coagulation Factor IX (Recombinant), Fc Fusion Protein INSTRUCTIONS FOR USE Read the Instructions for Use before you start using ALPROLIX and each time you get a refill. There may be new information.
More informationADVANCE PREPARATION OF INSULIN FOR PATIENTS TO ADMINISTER AT HOME
STANDARD OPERATING PROCEDURE ADVANCE PREPARATION OF INSULIN FOR PATIENTS TO ADMINISTER AT HOME First Issued July 08 Issue Version Two Purpose of Issue/Description of Change Planned Review Date To promote
More informationInstructions for Use Enbrel (en-brel) (etanercept) for injection, for subcutaneous use Multiple-dose Vial
Instructions for Use Enbrel (en-brel) (etanercept) for injection, for subcutaneous use Multiple-dose Vial How do I prepare and give an injection with Enbrel multiple-dose vial? A multiple-dose vial contains
More informationMcKinley T34 Syringe Driver Guidelines for Adult Supportive and Palliative Care
SH CP 94 McKinley T34 Syringe Driver Guidelines for Adult Supportive and Palliative Care Version: 3 Summary: Keywords (minimum of 5): (To assist policy search engine) Target Audience: McKinley T34 Syringe
More informationCHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY
CHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY Version 4.0 March 2016 Review date March 2018 Introduction It is the purpose of this policy to provide clear guidelines that
More informationHome Care Services HomeMed MedEQUIP Michigan Visiting Care Michigan Visiting Nurses Wheelchair Seating Service PROCEDURE
UNIVERSITY OF MICHIGAN HOSPITALS AND HEALTH CENTERS UMHHC-HCS: 253.054 First Approved Date: 3/2010 Home Care Services HomeMed MedEQUIP Michigan Visiting Care Michigan Visiting Nurses Wheelchair Seating
More informationSpecialist Palliative Care Audit and Guidelines Group (SPAGG)
Specialist Palliative Care Audit and Guidelines Group (SPAGG) Clinical Guideline for the Prescribing and Administration of Furosemide via continuous subcutaneous infusion (CSCI) for Heart Failure Patients
More informationAdministration of Injectable Medication by Healthcare Assistants (Band 3) Standard Operating Procedure
Administration of Injectable Medication by Healthcare Assistants (Band 3) Standard Operating Procedure DOCUMENT CONTROL: Version: 1 Ratified by: Quality Assurance Sub Committee Date ratified: 4 September
More informationEVER Pharma D-mine Pen Pen injector for Apomorphine 10 mg/ml
EVER Pharma D-mine Pen Pen injector for Apomorphine 10 mg/ml Instructions for Use with Dacepton 3 ml Cartridges Apomorphine hydrochloride hemihydrate solution for injection Subcutaneous Use TABLE OF CONTENTS
More informationStratis INSTRUCTIONS FOR USE. Needle-free Injection System. 0.5mL volume (+/-5%)
Stratis Needle-free Injection System INSTRUCTIONS FOR USE 0.5mL volume (+/-5%) Stratis English Symbols Glossary (Note: All symbols are derived from ISO 15223-1, Medical Devices - Symbols to be used with
More informationCare of the Dying Management in Severe Renal Failure
Care of the Dying Management in Severe Renal Failure Clinical Guideline Early diagnosis of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance
More informationEducation for Self Administration of Intravenous Therapy HOME IV THERAPY PICC. Portacath
HOME IV THERAPY PICC Portacath Who To contact Cardio-Respiratory Integrated Specialist Services (CRISS) Office hours 0800 1630 hours Ph: 364 0167 Weekends and after hours, phone Christchurch Hospital operator
More informationINSTRUCTIONS FOR USE
Comfort Injects 50 Comfort-in INSTRUCTIONS FOR USE English user manual 1 Introduction Thank you for choosing the Comfort in Needle free Injection system, developed with your comfort and convenience in
More informationDoncaster & Bassetlaw Cancer Locality. Palliative Care Core Formulary
Doncaster & Bassetlaw Cancer Locality Palliative Core Formulary Approved by Doncaster & Bassetlaw Hospitals NHS Foundation Trust Drugs and Therapeutics Committee. DJ14/2155 Oct 2014 Review date: Oct 2017
More informationSPAGG. Coversheet for Specialist Palliative Audit and Guideline Group Agreed Documentation
SPAGG Coversheet for Specialist Palliative Audit and Guideline Group Agreed Documentation This sheet is to accompany all documentation agreed by SPAGG. This will assist maintenance of the guidelines as
More informationINSTRUCTIONS FOR PREPARING AND GIVING AN INJECTION OF ENBREL POWDER
INSTRUCTIONS FOR PREPARING AND GIVING AN INJECTION OF ENBREL POWDER Introduction The following instructions explain how to prepare and inject Enbrel powder for injection. Please read the instructions carefully
More informationNormal Immunoglobulin (Human) 16%, solution for subcutaneous administration.
Normal Immunoglobulin (Human) 16%, solution for subcutaneous administration. Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about. It does not contain
More informationInstructions for Use. For use with. 10 mg vial
Instructions for Use For use with 10 mg vial Table of Contents Parts of the ZOMA-Jet 10... 1 Supplies you will need to mix a ZOMACTON 10 mg Vial... 2 Mix a ZOMACTON 10 mg vial... 3 Reset the ZOMA-Jet 10...
More informationGUIDELINES FOR PRESCRIBING AT THE END OF LIFE FOR PATIENTS WITH RENAL IMPAIRMENT (estimated glomerular filtration rate<30)
GUIDELINES FOR PRESCRIBING AT THE END OF LIFE FOR PATIENTS WITH RENAL IMPAIRMENT These guidelines have been produced in collaboration with Dr Lucy Smyth, Consultant in Renal Medicine, Royal Devon and Exeter
More informationANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL IMPAIRMENT
ANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL Doses of opiates must be proptional to current analgesic medication Please refer ALL patients on Methadone Ketamine to SPCT f advice. Patients
More informationUsing syringe pumps in palliative care
Using syringe pumps in palliative care Facilitator: Barbara Stone RN Ground rules Medication matching game Learning outcomes To identify the indications for using a syringe pump To discuss the general
More informationSUBCUTANEOUS AS REQUIRED & SYRINGE PUMP PRESCRIPTION & ADMINISTRATION RECORD (SPAR) Name: Address: Postcode: Date of Birth: NHS Number:
FILE IN PATIENT S COMMUNITY HEALTH RECORD FOLDER : SUBCUTANEOUS AS REQUIRED & SYRINGE PUMP PRERIPTION & ADMINISTRATION RECORD (SPAR) Abbreviations used in this document to be listed here with the full
More informationPEN USER MANUAL Byetta 5 micrograms solution for injection in pre-filled pen (exenatide)
PEN USER MANUAL Byetta 5 micrograms solution for injection in pre-filled pen (exenatide) Section 1. WHAT YOU NEED TO KNOW ABOUT YOUR BYETTA PEN Read this section completely before you begin. Then, move
More informationSCHEDULE 2 THE SERVICES
SCHEDULE 2 THE SERVICES A. Service Specifications Mandatory headings 1 4: mandatory but detail for local determination and agreement Optional headings 5-7: optional to use, detail for local determination
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Aimovig 70 mg solution for injection in pre-filled pen erenumab This medicine is subject to additional monitoring. This will allow quick identification of new
More informationStandard Operating Procedure for cannulation
Standard Operating Procedure for cannulation Effective date: 26.07.2017 Review due date: 31.03.2019 Original Author Name: Richard Metcalfe Position: PhD Student Date: 05.12.2012 Reviewer Name: Pippa Heath
More informationSOUTHERN HEALTH & SOCIAL CARE TRUST. Children & Young People s Directorate Procedure/Guidelines/Protocol Checklist & Version Control Sheet
Children & Young People s Directorate Procedure/Guidelines/Protocol Checklist & Version Control Sheet 1 Name of Procedure/Guidelines/ Protocol: PROCEDURE FOR PERIPHERAL ARTERIAL CANNULATION 2 Purpose of
More informationInstructions for Use. Welcome!
Instructions for Use Welcome! The AMJEVITA SureClick autoinjector is a single-use prefilled autoinjector. Consult your doctor if you have any questions about your dose. Your doctor has prescribed AMJEVITA
More informationFor patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.
Bedfordshire Palliative Care Palliative Care Medicines Guidance This folder has been produced to support professionals providing palliative care in any setting. Its aim is to make best practice in palliative
More informationI n s t r u c t i o n M a n u a l
I n s t r u c t i o n M a n u a l TABLE OF CONTENTS 2.5THE STARTER KIT...4 3.USING THE INJEX SYSTEM...5 3.1 PREPARING THE INJECTOR...5 1. INTRODUCTION TO THE INJEX TM SYSTEM...1 1.1PRODUCT DESCRIPTION...1
More informationNOTTINGHAM CHILDREN S HOSPITAL Nursing Guideline. P07 Care and Management of Children with a Totally Implantable Venous Access Device (Portacath).
NOTTINGHAM CHILDREN S HOSPITAL Nursing Guideline P07 Care and Management of Children with a Totally Implantable Venous Access Device (Portacath). Introduction A Portacath is a central venous access device
More informationIf viewing a printed copy of this policy, please note it could be expired. Got to to view current policies.
If viewing a printed copy of this policy, please note it could be expired. Got to www.fairview.org/fhipolicies to view current policies. Department Policy Code: D: PC-5575 Entity: Fairview Pharmacy Services
More informationLatex and Occupational Dermatitis Policy Incorporating Glove Selection
Latex and Occupational Dermatitis Policy Incorporating Glove Selection DOCUMENT CONTROL: Version: 3 Ratified by: Risk Management Sub Group Date ratified: 17 July 2013 Name of originator/author: Health
More informationPROCEDURE FOR THE USE OF McKINLEY T34 SYRINGE DRIVER TO DELIVER A CONTINUOUS SUBCUTANEOUS INFUSION IN PALLIATIVE CARE FOR ADULTS
PROCEDURE FOR THE USE OF McKINLEY T34 SYRINGE DRIVER TO DELIVER A CONTINUOUS SUBCUTANEOUS INFUSION IN PALLIATIVE CARE FOR ADULTS Policy authors Accountable Executive Lead Approving body Policy reference
More informationMMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life
MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life The following pages are guidelines for the management of common symptoms for a person thought to be
More informationSTEP-BY-STEP GUIDE TO SELF-INFUSION. Subcutaneous Administration of GAMMAGARD LIQUID
STEP-BY-STEP GUIDE TO SELF-INFUSION Subcutaneous Administration of GAMMAGARD LIQUID This handy guide will help you manage your subcutaneous administration of GAMMAGARD LIQUID. If you have questions on
More informationHumaPen SAVVIO INSULIN DELIVERY DEVICE INSTRUCTIONS FOR USE
HumaPen SAVVIO INSULIN DELIVERY DEVICE INSTRUCTIONS FOR USE For Single Patient Use Only www.lilly.ca INTRODUCTION HumaPen SAVVIO is designed for ease of use. You can give yourself multiple doses from one
More informationVolumetric Infusion Pumps - Delivering Volume with Accuracy
Volumetric Infusion Pumps - Delivering Volume with Accuracy INFUSION MANAGEMENT Accuracy you can rely on Paediatric Model 505 Model 500 Recognised in intensive care units, general wards and specialist
More informationUSER GUIDE BEST LIFE Insulin Pump
USER GUIDE BEST LIFE Insulin Pump 1 Table of contents 1. Safety Instruction... 4 2. Understanding BEST LIFE insulin pump... 6 The BEST LIFE insulin pump... 6 Menu structure... 8 Descriptions of Operation
More informationHow to Use ENBREL : Vial Adapter Method
How to Use ENBREL : Vial Adapter Method SETTING UP FOR AN INJECTION Select a clean, well-lit, flat working surface, such as a table. Take the ENBREL dose tray out of the refrigerator and place it on your
More informationSARASOTA MEMORIAL HOSPITAL NURSING PROCEDURE
SARASOTA MEMORIAL HOSPITAL NURSING PROCEDURE TITLE: ISSUED FOR: INTERMITTENT FLUID AND MEDICATION THERAPY Nursing DATE: REVIEWED: PAGES: RESPONSIBILITY: RN, LPN I, LPN II Per Job Description 03/81 8/09
More informationPROCEDURE. TITLE: Bedside Glucose Monitoring PC Laboratory. Issuing Department: Clinical Director Signature: Departments Involved:
PROCEDURE TITLE: Bedside Glucose Monitoring Issuing Department: Clinical Director Signature: Departments Involved: Laboratory Nursing Effective Date: 10/97 Review Dates: 09/01, 07/02, 05/13 Revision Dates:
More informationPENNINE LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE
PENNINE LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE Originally produced: July 2006 First Review: August 2009 Second Review: November 2011 For review November 2013 Approved
More informationStandard Operating Procedure for Use of Opioid Transdermal Patches in homes within NHS Sutton CCG
Standard Operating Procedure for Use of Opioid Transdermal Patches in homes within NHS Sutton CCG Introduction This procedure is intended to encourage good practice in the management of opioid transdermal
More informationCare in the Last Days of Life
Care in the Last Days of Life Introduction This guideline is an aid to clinical decision making and good practice in person-centred care for patients who are deteriorating and at risk of dying. The patient
More informationMND Just in Case kit Information for GPs
MND Just in Case kit Information for GPs What is the MND Just in Case kit? 2 Motor neurone disease (MND) is a progressive and terminal disease that results in degeneration of the motor neurones in the
More informationBLINDED MODE USERS GUIDE SUPPLEMENT
BLINDED MODE USERS GUIDE SUPPLEMENT BLINDED MODE user s guide SUPPLEMENT WARNING: The SEVEN PLUS when set to Blinded Mode using the Data Manager Software will not provide real-time continuous glucose readings,
More informationPLEASE READ THIS USER MANUAL BEFORE USE
USER MANUAL Humalog 200 units/ml KwikPen, solution for injection in a pre-filled pen insulin lispro PLEASE READ THIS USER MANUAL BEFORE USE USE ONLY IN THIS PEN, OR SEVERE OVERDOSE CAN RESULT Read the
More informationIMPORTANT: PLEASE READ. Don t
PATIENT/CAREGIVER INSTRUCTIONS FOR USE - ORENCIA (ABATACEPT) PREFILLED SYRINGE WITH BD ULTRASAFE PASSIVE TM NEEDLE GUARD WITH FLANGE EXTENDERS Getting started with ORENCIA therapy Did you receive self-injection
More informationSARASOTA MEMORIAL HOSPITAL. NURSING PROCEDURE INTRAOSSEOUS NEEDLE: INSERTION, CARE, AND REMOVAL (inv08) 12/18 12/18 1 of 7 RESPONSIBILITY:
SARASOTA MEMORIAL HOSPITAL TITLE: ISSUED FOR: NURSING PROCEDURE INTRAOSSEOUS NEEDLE: INSERTION, CARE, AND REMOVAL (inv08) Nursing DATE: REVIEWED: PAGES: 12/18 12/18 1 of 7 RESPONSIBILITY: PS1094 Insertion-
More informationPROCEDURE FOR BLOOD GLUCOSE MONITORING
PROCEDURE FOR BLOOD GLUCOSE MONITORING First Issued Issue Version Two Purpose of Issue/Description of Change Planned Review Date To promote safe and effective blood glucose monitoring using Trust equipment
More informationSupporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety
Agitation & Anxiety (Exclude or treat REVERSIBLE causes*) Patient is anxious / frightened, but lucid Patient is confused, agitated and / or hallucinating MIDAZOLAM 2.5-5mg s/c (Max total 24 hour dose of
More informationBlood Glucose Monitoring System. User Guide
Blood Glucose Monitoring System User Guide Table of Contents Introduction...2 Important Safety Instructions...2 About ipet PRO Blood Glucose Monitoring System...3 About ipet PRO Meter...4 About the ipet
More informationPalliative Care and the Critical Role of the Pharmacist. Arti Thakerar Education/ Palliative Care Peter MacCallum Cancer Centre
Palliative Care and the Critical Role of the Pharmacist Arti Thakerar Education/ Palliative Care Peter MacCallum Cancer Centre Overview What is palliative care Role of a pharmacist in palliative care Issues
More information